Accelerating introduction of new vaccines: barriers to introduction and lessons learned from the recent Haemophilus influenzae type B vaccine experience

Philos Trans R Soc Lond B Biol Sci. 2011 Oct 12;366(1579):2827-32. doi: 10.1098/rstb.2011.0046.

Abstract

Adoption of new vaccines in developing countries is critical to reducing child mortality and meeting Millennium Development Goal 4. However, such introduction has historically suffered from significant delays that can be attributed to various factors including (i) lack of recognition of the value of a vaccine, (ii) factors related to weak health systems, and (iii) policy considerations. Recently, the Global Alliance for Vaccines and Immunization (GAVI) supported efforts to accelerate the introduction of Haemophilus influenzae type b (Hib) vaccines in developing countries, which resulted in a significant surge in vaccine adoption by these countries. The experience with Hib vaccines, as well as similar efforts by GAVI to support the introduction of new pneumococcal and rotavirus vaccines, provides a strategy for new vaccine adoption that is reviewed in this paper, providing a useful model to help accelerate the uptake of other life-saving vaccines. This strategy addresses barriers for vaccine adoption by focusing on three major areas: (i) communications to increase awareness about the various factors needed for evidence-based decisions that meet a country's health goals; (ii) research activities to answer key questions that support vaccine introduction and long-term programme sustainability; and (iii) coordination with the various stakeholders at global, regional and country levels to ensure successful programme implementation.

Publication types

  • Review

MeSH terms

  • Decision Making
  • Developing Countries / economics
  • Haemophilus Infections / immunology
  • Haemophilus Infections / prevention & control*
  • Haemophilus Vaccines / administration & dosage
  • Haemophilus Vaccines / immunology
  • Haemophilus Vaccines / supply & distribution*
  • Haemophilus influenzae type b / immunology
  • Haemophilus influenzae type b / pathogenicity
  • Health Policy
  • Humans
  • Immunization Programs / economics
  • Immunization Programs / organization & administration*
  • International Cooperation
  • Public-Private Sector Partnerships
  • Vaccination

Substances

  • Haemophilus Vaccines